PROSTATE CANCER: RADIATION THERAPY APPROACHES ANDREW L. SALNER, MD FACR DIRECTOR HELEN & HARRY GRAY CANCER CENTER HARTFORD HOSPITAL, CT.

Slides:



Advertisements
Similar presentations
بسم الله الرحمن الرحيم ﴿و قل رب زدنى علماً﴾ صدق الله العظيم.
Advertisements

Is Radical Prostatectomy Adequate For High Risk Prostate Cancer?
Pulmonary Stereotactic Ablative Radiotherapy:
Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.
Management of locally advanced & metastatic prostate cancer Dr. Purvish. M. Parikh MD, DNB, PhD, FICP Professor & Head Department of Medical Oncology Tata.
Radiation Therapy in Prostate Cancer Current Status and New Advances Mahdi Aghili MD,AFSA Cancer Institute -Department of Radiation Oncology Associated.
Radiation Therapy for Treatment of Prostate Cancer Stephen Ko, M.D. Mayo Clinic Florida August 30, 2010.
The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.
IMRT vs. BRACHYTHERAPY FOR SOFT TISSUE SARCOMA. EXTERNAL RT IN STS NCI Trial (Yang JC et al, JCO 1998) Extremity / Superficial Trunk STS (n=141) LSS Alone.
Andrea Janeš Mentor: A. Žmegač Horvat
NEW OPTIONS IN PROSTATE CANCER TREATMENT Presented by Triangle Urology Associates, P.A.
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Prostate Cancer Int. 洪 毓 謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Radiotherapy for Kidney cancer
 These slides were extracted from a larger set of comprising a presentation entitled “Comparing Treatment Results of PROSTATE CANCER” dated 15_01_2013(3).
Dr. Rico Liu Consultant, Department of Clinical Oncology, Queen Mary Hospital Honorary Clinical Associate Professor, Department of Clinical Oncology, The.
Radiotherapy - the art of the invisible Terry Kehoe Consultant Clinical Scientist Head of Oncology Physics Edinburgh Cancer Centre “How to crack a walnut”
Comparison of Rectal Dose Volume Histograms for Definitive Prostate Radiotherapy Among Stereotactic Radiotherapy, IMRT, and 3D-CRT Techniques Author(s):
Patterns of Care in Medical Oncology Neoadjuvant and Adjuvant Treatment of Rectal Cancer.
Brachytherapy Medical radiation.
Conclusions HDR brachytherapy boost combined with moderate dose external beam irradiation resulted in a very high local control rate and few recurrences.
Howard M. Sandler, MD University of Michigan Medical School
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Mark L. Merlin, M.D. Radiotherapy Clinics of Georgia 7/14/2010 The Role of Radiation Therapy in the Management of Prostate Cancer.
Clinico-Dosimetric Correlation for Acute and Chronic Gastrointestinal Toxicity in Patients of Locally Advanced Carcinoma Cervix Treated With Conventional.
Cardiac events after treatment with high dose radiation therapy +/- chemotherapy for non-small cell lung cancer Linglong Tang, Anwen Liu, Daniel Gomez,
Prostate Support Group Dr Duncan McLaren Consultant Oncologist.
IMRT. 3DCRT vs IMRT Treated Volume Tumor Target Volume Intensity Modulation Treated Volume Critical structure Target Volume Collimator "Classical" Conformation.
Updated 5-year Biochemical Relapse-Free Survival after Prostate Brachytherapy Jenny P. Nobes St. Luke’s Cancer Centre, The Royal Surrey County Hospital,
Radiation Therapy in the Management of Cervical Carcinoma Patrick S Swift, MD Medical Director, Radiation Oncology Alta Bates Comprehensive Cancer Center.
Ten Year Outcomes In Men Under 60 Treated With Iodine-125 Permanent Brachytherapy As Monotherapy GU - Prostate Cancer: Novel Imaging (MRI,PET) & Brachytherapy.
PROSTATE CANCER: RADIATION APPROACHES for advanced disease
Robert Dreicer, M.D., M.S., FACP Chair Dept of Solid Tumor Oncology
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
Introduction/Aims There is less written about failure patterns after prostate brachytherapy (BT) alone or in combination with external beam radiotherapy.
High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.
Approaching early stage disease
Pre-Operative Therapy for Borderline Resectable Pancreatic Cancer: The Potential Role of Chemotherapy Robert A. Wolff, M.D. Associate Professor of Medicine.
Understanding Prostate Myths
Role of Radiation Therapy in Brain metastasis Bongkot Supawongwattana, M.D. Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chiang.
Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized Prostate Cancer David M. Spellberg M.D., FACS Naples Urology Associates,
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Prostate Cancer Jay L. Friedland, MD.
Stereotactic Body Radiation Therapy for Early Stage Prostate Cancer: Outcomes from a Single Institution Study Stereotactic Body Radiation Therapy for Early.
Carcinoma of the prostate. INTRODUCTION Prostate cancer is the most common cancer diagnosed and is the second leading cause of cancer death in men in.
Understanding Radiation Therapy Lecturer Radiological Science
Modern Radiation Oncology
Fig. 1 Frequency distribution of initial palliative treatment modalities used. EBRT, external beam radiotherapy. Initial palliative treatment modality.
Radiation therapy for Early Stage Prostate Cancer
Bladder Cancer and Prostatic Cancer
Copyright © 2012 American Medical Association. All rights reserved.
Feasibility of hippocampal sparing radiation therapy for glioblastoma using helical Tomotherapy Dr Kamalram THIPPU JAYAPRAKASH1,2,3, Dr Raj JENA1,4 and.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Prostate Cancer Jay L. Friedland, MD.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized and Advanced Prostate Cancer David M. Spellberg M.D., FACS Naples.
Fig. 4. Percentage of passing rate between clinical and 544 plans.
Volumetric Modulated Arc Therapy (VMAT) versus Intensity Modulated Radiation Therapy (IMRT) for Anal Carcinoma Heather Ortega, BSRT(T), CMD, Kerry Hibbitts,
Advances in the Treatment of Metastatic Prostate Cancer
Volume 72, Issue 5, Pages (November 2017)
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Radiation Therapy for Prostate Cancer
Clinical Radiation Oncology NMT232 L 10
Chapter 17 Intensity-Modulated Radiation Therapy
Neoadjuvant Adjuvant Curative Palliative
Figure 2 The evolution of brachytherapy for prostate cancer
Evaluating the Totality of Evidence
Presentation transcript:

PROSTATE CANCER: RADIATION THERAPY APPROACHES ANDREW L. SALNER, MD FACR DIRECTOR HELEN & HARRY GRAY CANCER CENTER HARTFORD HOSPITAL, CT

ARS ? ?

Conventional external beam Conformal external beam High-dose conformal Brachytherapy Brachytherapy/external beam Any of the above with androgen deprivation or chemotherapy 3-D IMRT Proton Ultra-high-dose High dose rate Low dose rate CHOICES!!!

Prostate Conformal therapy Conventional therapy Constraints: Volume rectum Volume of bladder Hips Conformal radiation therapy

Why IMRT? Treated Volume Tumor Target Volume Intensity Modulation Treated Volume Critical structure Target Volume Collimator "Classical" Conformation Critical structure Answer: great for treating donuts and bananas

IMRT

Fontenot, MDACC, IJROBP 2009

Percent of Rectal wall receiving high doses of radiation Plans run on 23 patients with prostate cancer Tufts, NEMC

Tomotherapy

Contemporary prostate brachytherapy: Trans-perineal approach

HIGH DOSE RATE “TEMPORARY” BRACHYTHERAPY

Quality of life after treatment for early-stage prostate cancer Talcott et al 2003 Prospective study Brachytherapy n = 80 Median age 64 years Max score 100 Min score 0

Quality of life after treatment for early-stage prostate cancer Talcott et al 2003 Prospective study External beam radiation N = 182 Median age 69 years Max score 100 Min score 0

Radiation Therapy Approaches  Many options  Must be tailored to meet patient needs  Highly conformal resulting in: Better tumor control Better tumor control Fewer side effects Fewer side effects  Comparable to other therapies over years

THANK YOU

Prostate Cancer Treatment: What’s Best for You Daniel P. Petrylak Professor of Medicine Columbia University Medical Center/NY Presbyterian Hospital

When does a patient see a medical oncologist Local disease: As “unbiased” opinion for local therapy High Risk Disease: Add hormone or chemotherapy to decrease risk of relapse Metastatic disease: Initiation of second line hormones, chemotherapy, radiation therapy

High-Risk CAP: The Options Surgery – Standard RP, wide/extended resection RP – Hormone therapy: NHT, AHT – ART – Chemotherapy: Neoadjuvant, adjuvant RT – EBRT with NHT and/or AHT – Dose escalation – EBRT with chemohormonal therapy – Other RT techniques HT alone New therapies NHT = neoadjuvant hormone therapy; AHT = adjuvant hormone therapy; ART = adjuvant radiotherapy. Payne, 2009.

Challenges for the Implementation of Multimodality Therapy High risk local therapy –Role of chemotherapy not defined –Investigational studies require long follow- up due to the natural history of disease –By selecting the highest risk patients, reduce the available patient pool Clinical trial accrual has been poor.